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Abstract
Background The benefit of adjuvant therapy in synovial sarcoma (SS) treatment is under debate. Long-term follow-up data 
are missing.
Methods SS patients treated in the consecutive trials CWS-81, CWS-86, CWS-91, CWS-96, CWS-2002-P, and the SoTiSaR-
registry till 2013 were analyzed.
Results Median age of 185 patients was 13.9 years (0.1–56)—with median follow-up of 7.4 years for 163 survivors. Most 
tumors (76%) were located in extremities. Size was < 3 cm in 58 (31%), 3–5 cm in 59 (32%), 5–10 cm in 42 (23%), 
and > 10 cm in 13 (7%) (13 missing). In 84 (45%) tumors, first excision was complete (R0 corresponding to IRS-I-group) 
and in 101 (55%) marginal (R1 corresponding to IRS-II-group). In a subsequent surgical intervention during chemotherapy, 
R0-status was accomplished in 23 additional IRS-II-group patients with secondary surgery. Radiotherapy was administered 
to 135 (73%), thereof 62 with R0-status and 67 R1-status (6 missing information). Adjuvant chemotherapy was administered 
to all but six patients. 5-year event-free (EFS) and overall survival (OS) was 82.9% ± 5.7 (95%CI) and 92.5% ± 3.9. Local and 
metastatic relapse-free survival was 91.3% ± 4.3 and 92.3% ± 4.1 at 5 years, respectively. In the multivariate analysis, tumor 
size and no chemotherapy were independently associated with EFS. Size and site were associated with OS. In a detailed 
analysis of local and metastatic events, tumor size was associated with an independent risk for developing metastases. No 
independent factor for suffering local recurrence could be identified.
Discussion Omission of chemotherapy in a non-stratified way seems not justified. Size governs survival due to high linear 
association with risk of suffering metastatic recurrence in a granular classification.
Keywords Synovial sarcoma · Soft-tissue sarcoma · Pediatric sarcoma · Adjuvant therapies · Chemotherapy · Radiotherapy
Introduction
Soft-tissue sarcomas represent nearly 8% of childhood 
malignancies. Synovial sarcoma (SS) is the most common 
non-rhabdomyosarcoma soft-tissue sarcoma (Goldblum 
2014; Pizzo and Poplack 2011), characterized by the spe-
cific translocation t(X;18). It typically affects the extremi-
ties of adolescents, as well as of young adults. The main 
age range is between 10 and 40 years. Pathological features 
are identical in all age groups (Goldblum 2014; Pizzo and 
Poplack 2011).
Whereas pediatric oncologists assumed that chemother-
apy might play an important role, and administered adju-
vant chemotherapy regardless of risk factors (Ferrari et al. 
1999, 2004; Schmidt et al. 1991; Ladenstein et al. 1993; 
Pappo et al. 1994; Okcu et al. 2001, 2003), adult oncologists 
considered SS as a tumor with uncertain chemosensitivity 
(Frustaci et al. 2001; Sarcoma Meta-analysis Collaboration 
1997; Brodsky et al. 1992; Bergh et al. 1999; Lewis et al. 
2000; Spillane et al. 2000; Trassard et al. 2001). Pediatric 
trials reported very satisfactory results with up to 75–80% of 
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survival rates (Ferrari  et al. 1999, 2004; Schmidt et al. 1991; 
Ladenstein et al. 1993; Pappo et al. 1994; Okcu et al. 2001, 
2003), better than those in adult series (Ferrari et al. 2004; 
Frustaci et al. 2001; Sarcoma Meta-analysis Collaboration 
1997; Brodsky et al. 1992; Bergh et al. 1999; Lewis et al. 
2000; Spillane et al. 2000; Trassard et al. 2001)—evolving 
the discussion if age per se is a risk factor (Hayes-Jordan 
et al. 2000) or if this is caused by the differing treatment 
approaches (Baldi et al. 2019; Tarkan et al. 2014; Italiano 
et al. 2009; Outani et al. 2019). Currently, treatment strate-
gies converge towards more common strategies. However, 
especially for adolescents, still existing controversies cause 
discussions. Apart from systemic treatment, there is also 
disagreement about the required local aggressiveness. 
While, some reported resections with free margins to be 
crucial, especially pediatric series reported no differences 
in resections with positive margins (Orbach et al. 2011). 
Summarized, adjuvant therapies in grossly resected SS are 
still a matter of debates.
Patients and methods
Patients treated 1980–2013 in the trials CWS-81 (Kosciel-
niak et al. 1992), CWS-86 (Koscielniak et al. 1999), CWS-
91 (Dantonello et al. 2009), CWS-96 (Modritz et al. 2005), 
CWS-2002-P (Koscielniak et al. 2013), and the registry 
CWS-SoTiSaR were eligible if (i) diagnosis was proven by 
central reference review (including molecular confirmation 
since 2000), (ii) no evidence of metastases existed, (iii) no 
previous treatment was performed, and (iv) the tumor was 
initially grossly resected.
All CWS-trials were prospective and approved by appro-
priate ethics committees. Written informed consent was 
obtained from patients, guardians/parents, or both (Dan-
tonello et al. 2008, 2009). Clinical information, treatment 
data, and outcome were available for all. Some had been 
included in previous analysis (pathological slides were 
reviewed for the purposes of those studies) (Stegmaier et al. 
2017; Scheer et al. 2016).
Disease was staged according to the clinical tumor-
node-metastases (TNM) classification (Harmer et al. 1970) 
which confines T1-tumors to the organ/tissue of origin, 
while T2-lesions invade contiguous structures and regional 
node involvement as N0 or N1, based on histological or 
clinical/radiological assessments (Baldi et al. 2019). Origi-
nally developed for rhabdomyosarcoma, but extended to 
other chemotherapy-sensitive pediatric STS, the Intergroup 
Rhabdomyosarcoma Study (IRS) post-surgical grouping 
system (Maurer et al. 1988) categorizes patients based on 
the extent of residual tumor after first surgery: primary com-
pletely excised tumors with negative microscopic margins 
(R0) correspond to IRS-I; primary grossly resected tumors 
with microscopic residual disease (R1): IRS-II; macroscopic 
residual disease after incomplete resection or biopsy (R2): 
IRS-III; and metastases at onset: IRS-IV (Maurer et al. 
1988).
Generally, a primary excision was attempted if complete 
and non-mutilating resection was considered feasible. Any 
re-surgery performed up to 4 weeks after biopsy/inadequate 
primary resection before any other treatment was defined 
as primary re-excision and considered in the IRS-system. 
The consecutive CWS-protocols recommended chemother-
apy in all patients. The regimens were VACA (vincristine, 
actinomycin-D, cyclophosphamide, adriamycin) in CWS-
81 (Koscielniak et al. 1992), and VAIA, which incorpo-
rates ifosfamide instead of cyclophosphamide, in CWS-86 
(Koscielniak et al. 1999) and in all protocols including and 
following CWS-96 (Modritz et al. 2005; Koscielniak et al. 
2013). The CWS-91-trial investigated therapy intensification 
with etoposide (EVAIA) (Dantonello et al. 2009). Since the 
CWS-96-protocol, the VAIA-regimen is used (Modritz et al. 
2005; Koscielniak et al. 2013).
Radiotherapy was recommended for all except for IRS-I 
(primary R0) patients, where it was only recommended in 
CWS-86 and CWS-91. According to the respective CWS-
protocol radiotherapy at doses of 32–54.4 Gy (when accel-
erated hyperfractionated) and 40–50 Gy if conventional 
fractionated dependent on response to chemotherapy and 
resection status was to be administered in analogy to recom-
mendations for patients with rhabdomyosarcoma (Kosciel-
niak et al. 1992, 1994, 1999; Dantonello et al. 2009; Modritz 
et al. 2005).
Best surgery was defined as the best surgical result at 
the end of treatment independent from the number of pro-
cedures. It was categorized as the presence of microscopic 
[R1] residual tumor or as resection with free margins [R0].
Statistical methods
Statistics were calculated using SPSS® 24 (IBM SPSS, 
Armonk, NY, USA). Comparison of distribution was per-
formed with the χ2-test. Event-free survival [EFS] and over-
all survival [OS] were calculated using the Kaplan–Meier 
estimator (Kaplan and Meyer 1958). For OS, time from diag-
nosis to death or last follow-up was calculated, for EFS time 
from diagnosis to first relapse/progression, death, or last 
follow-up. The local relapse-free survival [LRFS] was cal-
culated from diagnosis to local (included combined) relapse. 
Metastases-free survival [MFS] was calculated from diag-
nosis to the onset of distant metastases. Patients who died of 
their tumor after distant failure, prior to local progression/
relapse, were censored at the time of death in the analysis of 
LRFS. Confidence intervals [CI] for the Kaplan–Meier esti-
mator were computed using Greenwoods Formula (Green-
wood 1926) and are stated at the 95% level. For comparison 
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of EFS, OS, LRFS, and MFS levels, the log-rank test was 
used. The Cox proportional hazard regression model was 
used to assess the effects of each potential prognostic vari-
able on survival rates (Orbach et al. 2011). A stepwise 
variable selection procedure (combination of forward and 
backward selection techniques) was applied to the covariates 
with a p value of at least 0.05 in EFS, OS, LRFS, or MFS at 
the univariable analysis. Hazard ratios (HRs) with 95% CIs, 




Among 330 patients with localized SS, 185 had undergone 
initial gross resection, thereof 84 with primary free margins 
IRS-I/(R0) and 101 with primary positive margins IRS-II/
(R1). Gender distribution was balanced (Table 1). Median 
age was 13.9 years (first month of life–56.8). Localization 
of the primary tumor was: extremities 140 (76%), head–neck 
10 (5%), shoulder or hip 20 (11%), and trunk 12 (8%). Local 
invasiveness (T2) was reported in 49 (26%) and size > 5 cm 
in 59 (32%). Six patients (3%) had nodal involvement.
Treatment
Chemotherapy was given to all but six: 141 (76%) received 
the VAIA, 1 the EVAIA, and 30 (16%) the VACA regimen.
In the IRS-II/(R1) group, 23 of 101 patients underwent 
second surgical intervention only after the start of chemo-
therapy to obtain a tumor cell-free primary site. Therefore, 
in total, 107 (58%) achieved a R0-status as best surgical 
result at any time.
Radiotherapy was administered to 135 (73%): 45 out of 
84 (54%) IRS-I/(R0)-patients and 89 out of the 101 (88%) 
IRS-II/(R1) (detailed presentation in Fig. 1). The docu-
mented total dose ranged from 32 to 60 Gy, while the major-
ity received < 50 Gy.
Outcome
At last follow-up, 163/185 (88%) were alive. Median follow-
up for survivors was 7.4 years (0.7–31.1). Twenty patients 
died of disease, two of treatment toxicity (according to the 
documentations of the participating centers: 1. “cardiogenic 
shock, cachexia” in first-line therapy while receiving the 
VACA regimen, 2. “liver failure, organ failure” in relapse 
chemotherapy).
3-, 5-, and 10-year EFS was 87.9% ± 4.7, 82.9% ± 5.7 
and 75.2% ± 7.4. 3-, 5- and 10-year OS was 95.0% ± 3.1, 
92.5% ± 3.92 and 84.6% ± 6.7, respectively.
Pattern of relapse
39 patients developed recurrences, 16 local, 14 metastatic, 
4 at local and distant sites combined. For 5 patients, type of 
relapse was not specified (Table 2). 3-, 5-, and 10-year LRFS 
and MFS were 93.9% ± 3.5, 91.3% ± 4.3, 86.9% ± 5.9 and 
94.9% ± 3.3, 92.3% ± 4.1, 87.7% ± 6.1, respectively. Median 
time to local failure was 2.5 years. The latest local recur-
rences were documented at 7.7, 8.6, 11.5, and 16.0 years, 
respectively. Median time to distant failure without involve-
ment of the primary region was 2.7 years. The latest occur-
rence of metastases was documented at 4.0, 5.8, 6.2, and 
8.6 years.
The proportion of metastatic recurrences increased with 
larger tumor size. The rate of local relapses did not differ 
with size (Table 3).
Factors for survival
In the univariate analysis, factors associated with adverse 
EFS were large tumor size and no application of chemo-
therapy (Table 1, Fig. 1). Factors associated with adverse OS 
were tumor location at the head–neck, large tumor size, inva-
siveness (T2-status), and no application of chemotherapy. 
Survival was not associated with surgical margins.
In the Cox regression analysis, large tumor size and no 
application of chemotherapy were associated with adverse 
EFS. Large tumors and tumors localized at head–neck were 
associated with adverse OS (Table 4).
Factors for local and metastatic events
In the detailed evaluation of local and metastatic events, 
size and application of chemotherapy correlated with LRFS. 
Size, invasiveness (T-status) and chemotherapy correlated 
with MFS. In the Cox regression analysis, no independent 
factors for LRFS were identified. Size was associated with 
independent risk for MFS.
Chemotherapy
When we analyzed patients treated with cyclophosphamide-
based regimens (VACA) versus those treated with ifosfa-
mide-based regimen (VAIA) versus those without chemo-
therapy, patients treated with the VAIA or the VACA scheme 
did not show different outcomes (5-year EFS and OS were 
83.1% and 86.0% for VACA and 85.7% and 95.4% for VAIA, 
respectively), whereas 6 patients without chemotherapy did 
significantly worse (5-year EFS and OS were 22.2% and 
62.5%; p < 0.001).
Among those six patients treated with local therapy 
alone 2 were reported to be in ongoing complete first 
remission at 12.4 years (primary tumor size < 3 cm) and 
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Table 1  Univariate analysis of 185 IRS-I and IRS-II patients
N (%) 5 yr EFS
(95% CI)
p value 5 yr OS
(95% CI)
p value 5 yr LRFS
(95% CI)




 CWS 81 17 (9) 88.2 ± 15.3 0.862 87.8 ± 15.9 0.819 100% 0.912 93.8 ± 12.0 0.843
 CWS-86 27 (15) 81.5 ± 14.7 92.6 ± 9.8 88.6 ± 12.2 88.6 ± 12.2
 CWS-91 18 (10) 76.6 ± 20.2 88.2 ± 15.3 87.7 ± 16.1 88.1 ± 15.5
 CWS-96 59 (32) 85.9 ± 9.0 92.5 ± 7.1 91.3 ± 7.3 92.4 ± 7.3
 CWS 2002P 39 (21) 83.8 ± 12.0 97.3 ± 5.3 91.9 ± 8.8 94.7 ± 7.3
 SoTiSaR 25 (14) 75.1 ± 20.6 91.8 ± 10.8 91.3 ± 11.6 95.7 ± 8.4
Gender
 Female 94 (51) 87.9 ± 6.7 0.295 94.4 ± 4.7 0.133 94.3 ± 4.9 0.335 95.6 ± 4.3 0.254
 Male 91 (49) 77.6 ± 9.0 90.4 ± 6.3 88.0 ± 7.1 88.7 ± 7.1
Age (years)
  ≤ 10 36 (19) 88.6 ± 10.6 0.872 94.3 ± 7.6 0.926 91.2 ± 9.6 0.258 96.4 ± 6.7 0.053
 10–21 133 (72) 82.5 ± 6.7 92.8 ± 4.5 90.3 ± 5.3 93.5 ± 4.3
  ≥ 21 16 (9) 73.3 ± 22.3 85.6 ± 18.6 100% 73.3 ± 22.3
Site
 Extremities 140 (76) 84.1 ± 6.3 0.502 94.6 ± 3.9 0.017 92.1 ± 4.7 0.799 93.0 ± 4.3 0.431
 Head–neck 10 (5) 90.0 ± 18.6 100% 100% 100%
 Shoulder or hip 20 (11) 85.0 ± 15.7 84.4 ± 16.3 90.0 ± 13.1 94.7 ± 10.0
 Trunk 15 (8) 66.7 ± 23.9 80.0 ± 20.2 80.0 ± 20.2 76.9 ± 22.9
Size
  < 3 cm 58 (31) 89.8 ± 8.6 0.011 100%  < 0.001 89.8 ± 8.6 0.037 100% 0.002
 3–5 cm 59 (32) 91.2 ± 7.3 98.3 ± 3.3 98.2 ± 3.5 94.5 ± 6.1
 5–10 cm 42 (23) 75.4 ± 13.3 84.9 ± 11.2 84.8 ± 11.2 89.2 ± 10.0
  > 10 cm 13 (7) 53.8 ± 27.0 69.2 ± 25.1 84.6 ± 10.0 65.8 ± 27.6
 No information 13 (7)
Size (5 cm)
  ≤ 5 cm 119 (64) 90.8 ± 5.5 0.004 99.2 ± 1.6  < 0.001 94.3 ± 4.5 0.048 97.2 ± 1.6 0.005
  > 5 cm 59 (32) 70.6 ± 11.8 82.5 ± 9.8 85.5 ± 9.2 85.2 ± 9.6
 No information 7 (4)
T-status
 T1 130 (70) 86.2 ± 6.1 0.058 95.2 ± 3.7 0.040 91.6 ± 4.9 0.609 94.0 ± 4.3 0.032
 T2 49 (26) 73.1 ± 12.5 85.0 ± 10.4 89.4 ± 8.8 87.3 ± 9.6
 TX 6 (3)
N-status
 N0 170 (92) 82.2 ± 5.9 0.757 91.8 ± 4.3 0.857 90.5 ± 4.5 0.938 91.6 ± 4.3 0.725
 N1 6 (3) 100% 100% 100% 100%
 NX 9 (5)
IRS
  IRS-I 84 (45) 79.1 ± 8.8 0.119 89.9 ± 6.7 0.449 89.6 ± 6.9 0.459 89.8 ± 6.7 0.435
  IRS-II 101 (55) 86.3 ± 9.6 94.7 ± 4.5 92.9 ± 5.1 94.5 ± 4.7
Chemotherapy
 No 6 (3) 22.2 ± 37.6  < 0.001 62.5 ± 41.5 0.003 44.4 ± 43.5  < 0.001 75.0 ± 42.5 0.001
 VACA 30 (16) 83.1 ± 13.5 86.0 ± 12.7 92.7 ± 9.8 93.1 ± 9.2
 VAIA* 141 (76)
7 (4)
85.7 ± 5.88 95.4 ± 3.5 93.3 ± 4.3 93.1 ± 4.3
 No information
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0.7 years (size missing) after first diagnosis. One suffered 
local relapse at 1.8 years (primary size 5–10 cm); he is 
reported alive in second complete remission 10.2 years 
after first diagnosis. Two suffered combined relapses at 
0.3 years (primary tumor size 5–10 cm) and 0.5 years (size 
missing); both are dead of disease 0.5 and 2.8 years after 
diagnosis. One patient presented with metastatic relapse 
1.5 years (primary tumor size 3–5 cm) after diagnosis and 
was reported alive at 3.8 years.
Radiotherapy
Univariate analysis showed no significant correlation 
between radiotherapy and survival rates for the entire cohort.
Table 1  (continued)
N (%) 5 yr EFS
(95% CI)
p value 5 yr OS
(95% CI)
p value 5 yr LRFS
(95% CI)




 Yes 135 (73) 85.1 ± 6.3 0.189 95.3 ± 3.7 0.086 93.5 ± 4.3 0.155 92.1 ± 4.7 0.572
 No 43 (23) 73.2 ± 13.7 82.2 ± 12.2 82.6 ± 11.8 91.3 ± 9.4
 No information 7 (4)
Best surgery
 R0 107 (58) 81.7 ± 7.4 0.548 91.1 ± 5.5 0.581 90.9 ± 5.7 0.988 91.0 ± 5.7 0.475
 R1 70 (38) 84.7 ± 8.8 93.8 ± 5.9 91.2 ± 6.7 95.1 ± 5.5
 No information 8 (4)
Bold values indicate statistical significance
*Thereof 1 patient with EVAIA
Fig. 1  Pattern of relapse accord-
ing to surgery and radiotherapy
IRS II
(n=101)
best surgical result R1
n=70
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The analysis of merely IRS-I/(R0)-patients revealed that 
5-year EFS was 81.8 ± 11.4% for patients receiving radio-
therapy and 72.2 ± 15.5% for those who did not (supplemen-
tary table 1). The application of radiotherapy was also not 
associated with local or metastatic relapse risk.
For IRS-II/(R1)-patients, EFS was 86.7 ± 3.7% for 
irradiated (n = 89) and 77.8 ± 13.9% for non-irradiated 
patients (n = 9), while 5-year OS was 96.3 ± 2.1% and 
77.8 ± 13.9%, respectively. There was no significant asso-
ciation with local or metastatic recurrences (supplemen-
tary table 2).
In the subgroup of 23 IRS-II/(R1)-patients with second-
ary R0-resection while on chemotherapy, 6 did not receive 
radiotherapy. One of those 6 suffered combined relapse, 
whereas the 5 remaining were reported in ongoing first 
remission for 4.9 years (2.2–10.4). 17 did receive additional 
radiotherapy to the secondary R0-resection, and one suf-
fered metastatic and one local relapse (Fig. 1, supplementary 
table 2).
Small tumors
In the subgroup of those 56 patients with tumors < 5 cm and 
resection with negative margins IRS-I/(R0), 3-year-EFS 
was 94.6% ± 5.9. 5-year-EFS was 90.5% ± 8.0, 10-year-
EFS 79.1% ± 12.9, and the 5-year-OS 98.2% ± 3.5. 52/56 
received chemotherapy (38 VAIA, 14 VACA). 2 did not 
receive chemotherapy, while in 2 information was missing. 
With median follow-up of 7.5 years (0.6–31.1), 9/56 suf-
fered relapse, thereof 5 local, 3 metastatic, 1 unspecified. 
4/9 events occurred after 5.2 years.
In the subgroup of 63 patients with tumors < 5 cm and 
resection with positive margins IRS-II/(R1), 3-year-EFS was 
93.3 ± 6.3, 5-year-EFS 91.3 ± 7.3, 10-year-EFS 86.1 ± 9.8, 
and the 5-year-OS was 100%. This does not differ to the 
results of the IRS-I/(R0)-patients. All 63 patients received 
chemotherapy (53 VAIA, 9 VACA) with 1 missing informa-
tion. 8 suffered relapse with a median follow-up of 6.8 years 
(1.2–16.6), thereof 5 local, 2 metastatic, 1 unspecified. 
Median time to relapse was 3.2 years (1.3–16.0).
Secondary malignancies and long‑term toxicities 
due to radiotherapy and chemotherapy
Secondary malignancy was documented in 4 patients: [(1) 
benign ganglioneuroma and enchondroma of the fibula, (2) 
melanoma in situ, left foot, (3) embryonal carcinoma of the 
testis, and (4) basal cell carcinoma]. All patients achieved a 
remission of their secondary tumor.
Information on late effects was available for 142 patients. 
Thereof 72 patients (51%) did not suffer any late effect. 
Among those 70 other patients, mainly late sequelae in the 
extremities was generally documented by the participating 
centers. Among the 70 patients in the whole, 12 were docu-
mented with renal dysfunction, 8 with neuropathy, and 2 
with cardiomyopathy. 57 of those 70 patients were irradi-
ated. In 10 irradiated patients, specifically loss of function 
of their extremity was documented and in 3 other irradi-
ated patients leg length differences or growth problem of 
the limb.
Discussion
Whereas pediatric and adult studies mostly agree on factors 
influencing SS outcome (Ferrari et al. 1999, 2004; Schmidt 
et al. 1991; Ladenstein et al. 1993; Pappo et al. 1994; Okcu 
et al. 2001, 2003; Brodsky et al. 1992; Bergh et al. 1999; 
Lewis et al. 2000; Spillane et al. 2000; Trassard et al. 2001; 
Table 2  Failures and outcome 
according to IRS-group
CR complete remission, IRS Intergroup Rhabdomyosarcoma Stage (IRS-I free margins, IRS-II positive 
margins)
IRS-I IRS-I (%) IRS-II IRS-II (%)
All patients 84 100 101 100
No relapse 62 74 84 83
Relapse 22 26 17 17
Local 8 10 8 8
Metastatic 9 11 5 5
Combined 2 2 2 2
Not specified 3 4 2 2
Total failures 22 26 17 17
Alive 72 86 91 90
Dead 12 14 10 10
Median follow-up for survi-
vors, years (range)
7.6 (1.8–31.1) 7.1 (0.1–16.6)
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Koscielniak et al. 1992,  1999; Dantonello et al. 2009), 
there is no consensus on how patients should be classified 
to receive adjuvant therapy. In particularly, those factors 
essential for risk stratification in relation to chemotherapy 
have not yet been defined uniformly across age groups. All 
185 patients analyzed here are treated in prospective trials 
with median follow-up of more than 7 years for survivors. 
We can conclude that children, adolescents, and adults with 
grossly resected SS treated according to CWS recommenda-
tions have an excellent prognosis with an expected 5-year 
and 10-year OS of 93% and 85%, respectively. Regarding 
first relapse, patients had a local recurrence rate of 18%, a 
distant metastases rate of 16%, and a combined relapse rate 
of both local and distant lesions of 4%. Despite this excellent 
outcome, patients with large and very large tumors and those 
without chemotherapy are at independent risk for adverse 
events. The evaluation of distinct event types reveals that the 
risk of suffering metastatic recurrence is independently and 
moreover linearly associated with large tumors in a granular 
size classification. No independent factor for local recur-
rence was identified.
All except for six patients received chemotherapy. This 
small unselected subgroup has refused chemotherapy. Mul-
tivariate analysis proves independent impact of chemo-
therapy. However, results might be compromised by a low 
number in the non-chemotherapy group and can only be 
interpreted in consideration with the literature. In a prior 
attempt, the CWS and Italian IGC have reviewed the data of 
grossly resected SS in 2006. The study identified a subset 
of low-risk patients (IRS-I, < 5 cm), for which the omission 
of adjuvant chemotherapy might be recommended (Brecht 
et al. 2006). Consequently, according to the EpSSG-recom-
mendations 2005, those patients were treated with surgery 
only. Patients with tumors < 5 cm and/or resection with posi-
tive margins were recommended to have chemotherapy and 
radiotherapy (Ferrari et al. 2015). In the COG ARST0332 
trial (NCT00346164), for newly diagnosed non-rhabdomyo-
sarcoma soft-tissue sarcoma, starting in 2007, patients with 
low-grade tumor with either negative or positive micro-
scopic margins or high-grade tumor ≤ 5 cm with negative 
margins had not received adjuvant or further therapy. In 
2017, Ferrari et al. reported results of 3-year EFS of 90% 
in 60 patients with median follow-up of 5.2 years. All eight 
events were local recurrences. All were effectively salvaged. 
The authors consequently conclude that adequately resected 
SS < 5 cm, regardless of grade can be safely treated with a 
surgery only approach.
In our subgroup of those 56 patients with tumors < 5 cm 
resected with negative margins (IRS-I/R0), 3-year EFS was 
94.6% ± 5.9. This does not differ from the results without 
chemotherapy. In our series, 9/56 suffered relapse, thereof 
5 local, 3 metastatic, 1 unspecified with median follow-up 
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Fig. 2  EFS, OS, LRFS and MFS according to tumor size. LRFS and MFS according to patients’ age. LRFS and MFS according to chemotherapy
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follow-up for the Ferrari series is merely 5.2 years. Long-
term results are therefore highly anticipated. International 
cooperation with biological accompanying investigation 
would be needed to finally resolve this question.
In our subgroup of 63 patients with tumors < 5 cm and 
resection with positive margins (IRS-II/R1), 3-year-EFS was 
93.3% ± 6.3. This does not differ from the IRS-I/(R0)-group. 
There is neither a difference between IRS-I/(R0) and IRS-II/
(R1)-group, nor between best surgeries obtained in a second 
intervention during chemotherapy. However, patients with 
positive margins mostly received irradiation. Nevertheless, it 
should be underlined that the risk of metastatic relapse does 
not differ. Obviously, distant spread occurs before resection. 
Therefore, omission of chemotherapy might be an approach 
worth discussing in grossly resected SS < 5 cm regardless 
of resection margins.
There are very few evaluations that deal with the ques-
tion of which systemic anti-cancer drugs specific to SS 
improve outcome best (Baldi et  al. 2019; Riedel et  al. 
2018). Knowledge of effective substances mainly derives 
from retrospective analyses and basket trials. The patients 
in our series received the VACA (vincristine, adriamycin, 
cyclophosphamide, actinomycin-D) or the VAIA (vincris-
tine, adriamycin, ifosfamide, actinomycin-D) regimen. In 
the course of history, the combination VAIA has prevailed. 
In the present analysis, there was no significant difference 
between VACA and VAIA with a slightly better outcome 
with VAIA. Therefore, in patients who do not tolerate 
ifosfamide, the use of cyclophosphamide might not com-
promise outcome. Interestingly, the metastasis relapse-
free survival of patients >  = 21 years is worse than that of 
patients < 21 years. Even though the indication for chemo-
therapy in adult synovial sarcoma patients is not standard-
ized, the chemotherapy combination commonly used con-
sists of doxorubicin/ ifosfamide. However, in this series, all 
patients were treated according to the respective pediatric 
protocol. The nonetheless poorer metastasis-free survival of 
patients >  = 21 years raises the question of biological differ-
ences in different age groups.
CWS-protocols recommend radiotherapy for all SS 
patients except for IRS-I/(R0), where it was only recom-
mended in CWS-86 and CWS-91. There is no clear evi-
dence of the role of radiotherapy in IRS-I/(R0). A favorable 
trend with no statistically significant difference was shown 
(Ferrari et al. 2004). In the CWS-Italian co-analysis (Brecht 
et al. 2006), no benefit was observed, irrespective of tumor 
size. Consequently, no radiotherapy for IRS-I/(R0)-patients 
is recommended regardless of size and T-status in the CWS 
recommendations.
In patients with initial complete macroscopic resection 
with positive margins (IRS-II/R1), the indication for radio-
therapy is a matter of debate. Generally, it is considered 
as indicated. In the common analysis (Brecht et al. 2006), 
treatment results for IRS-II/(R1) patients were compara-
ble to those in IRS-I/(R0). Nearly all IRS-II/(R1) patients 
received radiotherapy. Nevertheless, data from Orbach et al. 
showed similar outcome regardless of irradiation in a sub-
set of 27 IRS-II/(R1) patients, thus suggesting that radio-
therapy may not be necessary after microscopic incomplete 
surgery (Orbach et al. 2011). Interestingly, in our IRS-II/
(R1) patients, the administration of radiotherapy was also 
not associated with improved survival or with reduced risk 
of local recurrence. In a closer look at the subgroup of those 
with R1-resection as best surgical result at the end of treat-
ment and treated without radiotherapy, relapse rate did not 
differ from the subgroup of R0 resected SS and of those 
treated with radiotherapy (Fig. 1, supplementary table 2).
Interestingly, the degree of surgery also lacked its prog-
nostic role—unlike others reported (Ferrari et al. 2004; 
Ladenstein et al. 1993; Pappo et al. 1994; Okcu et al. 2003; 
Harmer et al. 1970). The reasons that may partially explain 
differences might probably relate, at least in part, to the diffi-
culty of a precise definition of IRS-II and R1 due to adequate 
surgical approach and adequate surgical margins. However, 
chemotherapy affects not only the potential spread distant 
micro-metastases, but also the primary or tumor cells that 
might have remained in the primary tumor area after gross 
resection. In this way, chemotherapy can also be considered 
as local therapy. It is a generally accepted fact that prognos-
tic factors should not be interpreted apart from the particu-
lar study population and the therapeutic context. Beyond 
that, the aggressiveness of local therapy cannot be assessed 
correctly when considered independently of systemic ther-
apies. To put this in more general terms, chemotherapy 
might reduce the required aggressiveness. Differences in the 
applied systemic therapies might explain the contradictory 
or inconsistent results (Tarkan et al. 2014; Yaser et al. 2014; 
Salcedo-Hernandez et al. 2013; Vining et al. 2017). How-
ever, in clinical use, this interpretation would be important 
in complicated local situations.
Unfortunately, grading was not available for many of the 
patients included during the long recruitment period. In for-
mer times, synovial sarcoma was generally considered as a 
high-grade tumor (Ferrari et al. 2015), whereas nowadays, 
tumor grade is considered to be a predictive factor (Bianchi 
et al. 2017; Guillou et al. 2004). Nevertheless, our group 
could not provide evidence for this (Stegmaier et al. 2017).
The consecutive CWS studies had general follow-up rec-
ommendations. These were not sarcoma subtype specific. 
There were only slight differences between the different 
studies. Regular routine examinations were recommended 
for 5 years after completion of therapy. Summarized, in the 
first year, regular cross-sectional imaging of the primary 
tumor region, preferably MRI, was recommended at 4-month 
intervals. In the following 2 years, at intervals of 6 months. 
After 3 years, intervals of 6–12 months were recommended. 
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Chest-X-ray or CT thorax (at least every 6 months), ultra-
sound abdomen/pelvis (at least every 6 months), and a 
bone scan (risk-adapted, once a year) were recommended 
in the first year. Chest X-ray was recommended at 6-month 
intervals in the second year, followed by annual checks 
until 5 years after completion of therapy. From the 6th year 
onwards, controls by sonography/cross-section imaging of 
the primary tumor region and lung imagings were recom-
mended with frequency at the discretion of the responsible 
physician. Interestingly, despite the known heterogeneity 
of soft-tissue sarcoma and in particularly of the group of 
NRSTS, there are no detailed subtype-specific follow-up 
recommendations. In this series of grossly resected SS, 
median time to local failure was 2.5 years. Median time to 
distant failure without involvement of the primary region 
was 2.7 years. This result might suggest regular imaging fol-
low-up examinations at closer intervals (e.g., 4 months) until 
3 years after the end of therapy, and then an extension of the 
intervals. The latest local recurrences were documented at 
11.5 and 16.0 years and the latest occurrence of metastases 
at 6.2 and 8.6 years, respectively. Annual control examina-
tions until ~ 10 years after the end of therapy might seem 
reasonable. The possibility of a very late relapse should 
be known by the treating physicians. Most relapses are, 
however, detected due to clinical signs and symptoms and 
the patients should be educated to contact their oncologist 
immediately in case of unclear symptoms. It seems reason-
able to incorporate the identified risk factors in the follow-up 
recommendations, e.g., patients with tumors < 5 cm have a 
significantly lower risk of suffering metastatic recurrence 
(whereas 72% of patients with a SS > 10 cm suffer metastatic 
relapse, Table 3). In the future, it will be important to also 
incorporate the constantly growing knowledge of tumor biol-
ogy or rather biological risk factors into the recommenda-
tions for follow-up care.
In summary, to our knowledge, this analysis represents 
the largest series of grossly resected SS treated in prospec-
tive risk-adapted trials so far. It adds interesting data that 
could be helpful in treatment decisions:
(1) Tumor size governs survival in grossly resected SS 
regardless of all other factors. Moreover, tumor size is 
linearly associated with the risk of suffering metastatic 
relapse. Therefore, a granular size classification seems 
reasonable.
(2) A non-risk stratified omission of chemotherapy results 
in a significant deterioration in outcome.
(3) In those patients with tumors < 5 cm resected with neg-
ative margins, survival is not superior with chemother-
apy. Though long-term survival data of those treated 
without chemotherapy are highly anticipated, omission 
of chemotherapy seems justified.
(4) The survival of patients with tumors < 5 cm resected 
with positive margins does not differ from those with 
negative margins.
(5) Moreover, no independent factor for suffering local 
recurrence could be identified.
(6) This series is in contrast to many other SS series that 
identify free margins as crucial factor. However, this is 
a series where almost all patients have received chemo-
therapy. The required aggressiveness of local therapy 
cannot be assessed independently of the systemic ther-
apy administered.
Summarized, patients with grossly resected SS treated 
according to CWS recommendations have an excellent prog-
nosis. A subgroup probably does not require chemotherapy. 
Whether size and surgery can serve as criteria for the omis-
sion of chemotherapy needs to be tested in prospective pre-
clinical and clinical studies. Biology signature may predict the 
outcome and may be used for patients’ stratification to better 
identify patients more appropriate to receive systemic therapy.
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